SCHEMBL24256678

SCHEMBL24256678

COc1ccc(CCNC(=O)c2sc3nc4c(c(C)c3c2N)CCC4)cc1OC

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.67
SMN1; SMN2 Q16637 3/20 0.67
HPGD P15428 1/20 0.67
MTOR P42345 1/20 0.61
MAPT P10636 4/20 0.55
HTT P42858 1/20 0.55
EEF2K O00418 1/20 0.54
ALDH1A1 P00352 3/20 0.52
USP28 Q96RU2 1/20 0.52
USP25 Q9UHP3 1/20 0.52
NAMPT P43490 2/20 0.52
GAA P10253 2/20 0.49
KMT2A Q03164 1/20 0.49
CHRM4 P08173 4/20 0.49
POLB P06746 2/20 0.48
TP53 P04637 1/20 0.48
FLT1 P17948 1/20 0.47
LRRK2 Q5S007 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24256858 0.88 MTOR (0.63) LMNASMN1; SMN2HPGDMTORMAPT
SCHEMBL24256612 0.84 MTOR (0.60) LMNASMN1; SMN2HPGDMTORMAPT
SCHEMBL24256709 0.83 MTOR (0.61) LMNASMN1; SMN2HPGDMTORMAPT
SCHEMBL24256707 0.82 MTOR (0.58) LMNASMN1; SMN2HPGDMTORMAPT
SCHEMBL24256963 0.82 SMN1; SMN2 (0.50) LMNASMN1; SMN2HPGDMTORMAPT
SCHEMBL13568228 0.80 LMNA (1.00) LMNASMN1; SMN2HPGDMTORMAPT
SCHEMBL24256847 0.77 USP25 (0.69) MTORUSP28USP25
SCHEMBL22644970 0.74 NAMPT (0.58) LMNAMTORMAPTUSP28USP25
SCHEMBL24256669 0.74 MTOR (0.48) LMNASMN1; SMN2HPGDMTORMAPT
SCHEMBL24256357 0.73 MTOR (0.53) LMNASMN1; SMN2HPGDMTORMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
WO-2022035806-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP8 LMNA 4062/4885SMN1; SMN2 1921/4885HPGD 2308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.